Poster
149
(#149) A Quantitative Survey-based Study of Patient Preferences for a Long-acting Injectable Antipsychotic Administered Once Every 2 Months for Schizophrenia
Psych Congress 2025
Abstract: Long-acting injectable (LAI) antipsychotics with dosing intervals >1 month are becoming increasingly available for the treatment of schizophrenia. This study investigated patient preferences for a hypothetical LAI antipsychotic administered once every 2 months.
An online survey, including a discrete-choice experiment (DCE), was conducted in Europe and North America to quantify the strength of preference for an LAI antipsychotic administered once every 2 months and to identify factors associated with its acceptance among patients with schizophrenia.
Survey responses were received from 212 clinically stable patients with schizophrenia. Overall, 83% of 106 patients receiving a once-monthly LAI antipsychotic and 71% of 106 patients taking an oral antipsychotic indicated that they would be willing or open-minded to try an LAI antipsychotic administered once every 2 months. Primary motivations for trying an LAI given once every 2 months were 'to not have to think of taking the medicine as often' (44%) and feeling 'more free to live my life the way I want to' (39%).
Among 190 patients taking a once-monthly LAI antipsychotic or daily oral antipsychotic who completed the DCE, symptomatic improvement, reduced hospitalization risk, and feeling less sedated were the dominant drivers of treatment acceptance. For the attribute assessing preferences for route and frequency of administration, results showed patients prefer the form of treatment they are currently taking over other options.
An LAI antipsychotic given every 2 months may be acceptable to patients with schizophrenia, especially those currently receiving a once-monthly LAI antipsychotic. Treatment effectiveness and safety remain key determinants of acceptability.
Short Description: This study, an online survey, investigated patient preferences for a hypothetical long-acting injectable (LAI) antipsychotic given once every 2 months for the treatment of schizophrenia. Patients expressed positive views of an LAI antipsychotic administered once every 2 months and valued having fewer injections and appointments, which reduced treatment burden and increased their sense of freedom. Treatment effectiveness and safety remained the most important factors influencing treatment acceptability.
Name of Sponsoring Organization(s): Otsuka Pharmaceutical Development & Commercialization Inc. (Princeton, NJ, USA) and H. Lundbeck A/S (Valby, Copenhagen, Denmark).
An online survey, including a discrete-choice experiment (DCE), was conducted in Europe and North America to quantify the strength of preference for an LAI antipsychotic administered once every 2 months and to identify factors associated with its acceptance among patients with schizophrenia.
Survey responses were received from 212 clinically stable patients with schizophrenia. Overall, 83% of 106 patients receiving a once-monthly LAI antipsychotic and 71% of 106 patients taking an oral antipsychotic indicated that they would be willing or open-minded to try an LAI antipsychotic administered once every 2 months. Primary motivations for trying an LAI given once every 2 months were 'to not have to think of taking the medicine as often' (44%) and feeling 'more free to live my life the way I want to' (39%).
Among 190 patients taking a once-monthly LAI antipsychotic or daily oral antipsychotic who completed the DCE, symptomatic improvement, reduced hospitalization risk, and feeling less sedated were the dominant drivers of treatment acceptance. For the attribute assessing preferences for route and frequency of administration, results showed patients prefer the form of treatment they are currently taking over other options.
An LAI antipsychotic given every 2 months may be acceptable to patients with schizophrenia, especially those currently receiving a once-monthly LAI antipsychotic. Treatment effectiveness and safety remain key determinants of acceptability.
Short Description: This study, an online survey, investigated patient preferences for a hypothetical long-acting injectable (LAI) antipsychotic given once every 2 months for the treatment of schizophrenia. Patients expressed positive views of an LAI antipsychotic administered once every 2 months and valued having fewer injections and appointments, which reduced treatment burden and increased their sense of freedom. Treatment effectiveness and safety remained the most important factors influencing treatment acceptability.
Name of Sponsoring Organization(s): Otsuka Pharmaceutical Development & Commercialization Inc. (Princeton, NJ, USA) and H. Lundbeck A/S (Valby, Copenhagen, Denmark).
